All studies
Active not recruitingPHASE1INTERVENTIONAL

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

This early-stage clinical trial is looking at a targeted medicine called sotorasib for adults with advanced or spreading solid tumours. Researchers want to see how safe sotorasib is when taken on its own or alongside other cancer medicines, such as chemotherapy or immunotherapy. The trial is specifically for people whose cancer cells carry a faulty gene called KRAS G12C. This faulty gene sends constant signals that cause cancer cells to grow and multiply. Sotorasib is designed to stick to the abnormal KRAS G12C protein and switch off its growth signal. Because this is a Phase 1 study, the main aim is to check safety, find the best doses, and watch for side effects. Doctors will also monitor whether the treatments help slow down or shrink the tumours.

At a glance

Status
Active not recruiting
Phase
PHASE1
Sponsor
Amgen
Enrolment target
610
Start
17 Dec 2019
Estimated completion
05 Dec 2027

What is this study about?

Inside our bodies, genes act as instruction manuals for our cells. Sometimes, a gene called KRAS develops a specific fault known as the G12C mutation. This mutation causes a switch inside cancer cells to get stuck in the 'on' position, prompting the tumour to grow and spread. This genetic change can appear in several types of solid cancers, including bowel and lung cancers.

Sotorasib is a targeted medicine developed to specifically block this broken switch. While sotorasib can work well on its own, cancer cells can sometimes find alternative ways to keep growing. To tackle this, researchers in this trial (called CodeBreak 101) are testing sotorasib in combination with various other established cancer drugs, such as chemotherapies, immunotherapies, and other targeted treatments.

This is a Phase 1 trial, which is an early step in testing new medical treatments. The primary purpose is to find out how safe these drug combinations are, what side effects they might cause, and which doses work best together. Taking part helps researchers learn whether combining treatments could offer better control over advanced tumours in the future.

Key takeaways

  • CodeBreak 101 tests the targeted drug sotorasib alone or combined with other cancer medicines.
  • It is for adults with advanced solid cancers that have the KRAS G12C genetic mutation.
  • The primary goal of this Phase 1 trial is to test safety, find safe doses, and track side effects.
  • Treatment includes swallowing tablets and attending regular hospital visits for scans and tests.
  • Participation is entirely voluntary, and you can withdraw at any point.

Who may be eligible?

This trial is open to adults aged 18 and older who have an advanced solid tumour that cannot be removed with surgery or has spread to other parts of the body (metastatic cancer). To join, a lab test on a tumour sample must confirm that the cancer carries the specific KRAS G12C mutation.

The trial is not suitable for everyone. People cannot take part if they have a primary brain tumour, or if cancer spread to the brain or spinal cord is active, untreated, or causing symptoms. This is to ensure patient safety and avoid confusing side effects.

Additionally, participants must be able to swallow tablets, as sotorasib is taken by mouth. Those with severe digestive conditions that stop medicines from being absorbed properly, or people who have had a heart attack within the past six months, will not be eligible.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I have been diagnosed with an advanced or metastatic solid cancer.
  3. My cancer has been tested and confirmed to have the KRAS G12C mutation.
  4. I am able to swallow tablets and do not have major stomach or gut problems.
  5. I have not had a heart attack in the last 6 months.
  6. I do not have active or untreated cancer spread in my brain or spinal cord.
Answer every question to see your result.

What does participation involve?

If you join this study, you will take sotorasib by mouth as tablets, either on its own or along with another cancer treatment, which may be given as tablets or through a drip into a vein (intravenously). You will need to visit the hospital clinic regularly for health checks, blood tests, heart traces (ECGs), and imaging scans such as CT or MRI scans to monitor how your body is handling the treatment. You will be closely followed by a specialist cancer team throughout the study. You can remain on the study for as long as the treatment is helping your cancer and you do not experience unacceptable side effects, though you may choose to stop at any point.

Potential risks and benefits

The possible benefit of taking part is that the treatment may help shrink your tumour, slow down cancer growth, or relieve some symptoms, although this cannot be guaranteed. However, all cancer medicines carry risks. Possible side effects include fatigue, nausea, diarrhoea, liver irritation, or skin rashes, and some combinations could cause more severe or unexpected reactions. Taking part is completely voluntary. You are free to leave the trial at any time without giving a reason, and doing so will never affect your standard NHS care.

Locations (90)

  • Arizona Oncology Associates Professional Corporation
    Verified postcode
    Tucson, United States
  • City of Hope National Medical Center
    Verified postcode
    Duarte, United States
  • University of California San Diego Moores Cancer Center
    Verified postcode
    La Jolla, United States
  • Loma Linda University Cancer Center
    Verified postcode
    Loma Linda, United States
  • University of Southern California, Norris Comprehensive Cancer Center
    Verified postcode
    Los Angeles, United States
  • University of California Davis Medical Center
    Verified postcode
    Sacramento, United States
  • University of California San Francisco Mission Bay Campus
    Verified postcode
    San Francisco, United States
  • University of California Los Angeles
    Verified postcode
    Santa Monica, United States
  • Rocky Mountain Cancer Centers Denver Midtown
    Verified postcode
    Denver, United States
  • Sarah Cannon Research Institute
    Verified postcode
    Denver, United States
  • Yale New Haven Hospital
    Verified postcode
    New Haven, United States
  • Norwalk Hospital
    Verified postcode
    Norwalk, United States

Common questions

What is the KRAS G12C mutation?

It is a specific genetic fault inside some cancer cells that causes them to produce an abnormal protein, constantly telling the cancer to grow.

What is the purpose of a Phase 1 trial?

Phase 1 trials are early-stage studies designed to check the safety, find the right dose, and monitor the side effects of new medicines or new drug combinations.

How is sotorasib taken?

Sotorasib is taken orally as tablets. Depending on which group of the trial you join, you may also receive other medicines by mouth or through a drip.

Do I have to pay to take part in this trial?

No, the clinical trial medicines and study-related tests are provided free of charge, and some travel expenses may be covered.

Can I leave the study if I change my mind?

Yes. You have the right to withdraw from the trial at any time, and your medical team will help you transition to other care options.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.